Greg Duncan

• Lead board of directors and executive team to develop a compelling strategic plan and market position for the company, focused primarily on developing non-opioid, Nav 1.7 voltage-gated sodium channel inhibitors to treat cancer related pain, including chemotherapy induced neuropathic pain. • Merged public entity Virios Therapeutics, Inc. (VIRI) with privately held Wex Pharmaceuticals, concurrent with strategic financing to expand pipeline of development candidates to treat pain and fatigue related disorders. • Executed successful IPO Q4 2020 for DWTX predecessor company Virios Therapeutics, Inc to fund late-stage pain and long-Covid research programs through value accretion milestones. • Raise capital (equity, grants, debt) to fund operations and development candidates to value creation milestones (e.g. IP generation, research program selection, and IND through P3 activities for a novel new therapeutic candidate.

• Scaled private capital (Domain, Lumira, Masters Capital and CF Foundation) to advance pre-clinical, Phase 1 and Phase 2b clinical programs, including the largest global Phase 2 study conducted in the Cystic Fibrosis research pipeline. • Serve as the primary spokesperson for the company, establishing and communicating the company’s strategy and value to investors and customers at both scientific congresses and industry and investor meetings.

• Served as an executive committee member tasked with setting the strategic direction for UCB’s global specialty biopharma business, and managing annual delivery of the global $4B P&L. • Full P&L responsibility for UCB’s $1.5B North American (NA) business including the development of a Canadian affiliate. Notably, achieved double-digit regional top/bottom line growth as these results include incremental investment to launch Neupro in 2012 and Vimpat becoming the top epilepsy launch in US history. • Governed UCB’s mid-to-late-stage R&D portfolio and represented UCB to investment community, both standard quarterly reviews and customized events. • Lead UCB’s US evolution from primary care focused portfolio (Zyrtec, Xyzal) to specialty focused entity to support the launch of new specialty portfolio (Cimzia, Vimpat, Neupro). • Recruited, managed and developed a diverse, highly competent North American Leadership Team (10 of 12 new members recruited over three-year tenure).

• Managed Pfizer’s $1.5B business in Latin America, inclusive of double-digit revenue/EBIT growth. • Served on PhRMA Latin America working group tasked with executing progressive free-trade agreements and improving patent protection across the region. • Responsibilities included an unusual array of complex investments, management of a variety of business models, blended Rx/OTC portfolios and intellectual property issues. • Reorganized LA structure to enhance focus on two key growth markets (Argentina and Venezuela). • Management and coordination of all LA functions representing 4,300 colleagues throughout the region.

• Key member of US Leadership team managing Pfizer’s $26.5B US pharmaceutical business, enabling US division to consistently meet growing income targets (65% of corporate revenue). • Charged with managing the full Rx portfolio in the US including: -Lipitor, the worlds largest brand, grew by $2.1B (40%) from 2002-2005 -Zoloft #1 US antidepressant with sales of $2.6B -Norvasc #1 prescribed antihypertensive in US market -Viagra which posted global best 60% market share in ED category -Zyrtec #1 selling agent in the antihistamine market with sales of $1.2B -Celebrex sales growth of 22.9% to $1.4B -Lyrica launch achieved 150% target and set the foundation for what is currently a $3B per year brand for the treatment of DPN, PHN and epilepsy -Sutent became #1 treatment for Renal Cell Carcinoma and GIST • Leadership and development of six Group Vice Presidents, 400 marketers and $1.2B in promotional expenses invested in the plans to support 40 brand, customer and functional specialist teams (managed market, relationship marketing, e-marketing, media, PR, multicultural and environment marketing). • Served as one of two senior commercial leaders on Pfizer’s Global Development Review Committee (GDRC) tasked with prioritizing and endorsing Pfizer’s annual $8B R&D programs. • Appointed by the Pfizer Executive Leadership Team to participate in a host of investor-related activities including quarterly earnings briefings. Advocated for Pfizer with key investors and banks.

• Leader for $4B Global CNS portfolio including Zoloft, Aricept, Geodon and Relpax. • Managed Pfizer’s four Global Commercial Teams, assisting affiliates in preparing to execute CNS launches around the globe. • Senior commercial executive tasked with evolving the CNS development program.

• Served as member of Board of Directors for the Research, Manufacturing and Commercial Entity. • Developed and the delivery of the UK annual operating plan. • Led UK operations to achieve market leading position and advance from 7th largest affiliate to 3rd largest in Pfizer universe. • Co-chair European Pricing Committee.

• Chaired the Operational Alliance Committee for Pfizer/Eisai Alzheimer’s (AD) alliance. • Responsible for the global launch of Aricept, a $4B/annum asset that set the standard for launch excellence in the AD market. • Developed and executed the Lifecycle management plan and medical education required to change the treatment standard for AD and support Aricept.

• Responsible for the US launch of $4.5B/annum antidepressant for the treatment of Depression, OCD, Panic Disorder, PMDD, social phobia and PTSD. • Managed the development, validation and introduction of PRIME-MD (Primary Care Recognition of Mental Health Disorders) to support increased recognition and treatment of mental health disorder in primary and secondary care-validation published in JAMA: 1999, 282 (18): 1787.